Due to advances in cancer immunotherapy, including positive results from clinical trials testing new agents and combinations, emerging new technologies for measuring aspects of immunity, and novel candidate biomarkers from early phase trials, the SITC Immune Biomarkers Task Force has reconvened to review the state of the art, identify current hurdles to further success and to make recommendations to the field.
Topics being addressed by individual working groups include:
In the video below, published by OncLive, watch as current SITC President Dr. Lisa Butterfield discusses the Immune Biomarkers Task Force.
View current and past Task Force members via the links below:
Validation of Biomarkers to Predict Response to Immunotherapy in Cancer (two-part white paper) Journal for ImmunoTherapy of Cancer, November 2016
Novel Technologies and Emerging Biomarkers for Personalized Cancer Immunotherapy Journal for ImmunoTherapy of Cancer, January 2016
Systematic Evaluation of Immune Regulation and Modulation Journal for ImmunoTherapy of Cancer, March 2017
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy Journal for ImmunoTherapy of Cancer, May 2017
Click here to view a complete list of current and past published Immune Monitoring Technology Primers in the Journal for ImmunoTherapy of Cancer (JITC).
SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: Online resources and useful tools – a compass in the land of biomarker discovery Journal of Translational Medicine, September 2011
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers Clinical Cancer Research, May 2011
Immuno-Oncology Biomarkers 2010 and Beyond: Perspectives from the iSBTc/SITC Biomarker Taskforce Journal of Translational Medicine, December 2010
A Systematic Approach to Biomarker Discovery; Preamble to "the iSBTc-FDA Taskforce on Immunotherapy Biomarkers" Journal of Translational Medicine, December 2008
NCI/CCR and SITC co-sponsored a 2016 Biomarkers meeting to review the state of the art, discuss current hurdles to further success, and consider recommendations to move the field forward.
The main goals were to provide updated information to a wide audience and solicit stakeholder participation in promoting successful immune biomarker research.
A report of this meeting was published in the Journal for ImmunoTherapy of Cancer (JITC) in March 2017. Click here to read Immunotherapy Biomarkers 2016: Overcoming the Barriers. Also, to learn more about the event and its schedule, click here.
Be Part of the Breakthrough at the Charles River World Congress on Animal Models in Drug Discovery & Development. Boston | September 26-27, 2017 http://breakthroughs.criver.com/index.html
Use of mAb-based immunotherapies has resulted in major improvements in treatment of B-cell neoplasms, but patients can relapse, succumbing to the disease. An alternative approach that destroys tumor cells including cancer stem cells is, thus, needed urgently. ...
According to the cited pharma company document within, out of Hemel Hempstead, England, May 10, 2017, Dinutuximab beta, originally developed by the Vienna-based biotech company Apeiron Biologics for neuroblastoma, was previously available in Europe under ...
The European Commission has recently approved dinutuximab beta for high risk neuroblastoma patients over the age of 12 months, making it the only approved immunotherapy in Europe for this group of patients. In this exclusive interview with Oncology Central, ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org